Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumannii

13 Dec 2022

Abstract excerpt

New antimicrobials are needed for the treatment of extensively drug-resistant Acinetobacter baumannii . The de novo pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is a validated drug target for malaria and human autoimmune diseases. We provide genetic evidence that A. baumannii DHODH ( Ab DHODH) is essential for bacterial survival in rodent infection models. We chemically validate the target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to HIV/AIDS drug development and treatment
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36512492
DOI: 10.1073/pnas.2213116119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumanniiPMID 36512492Read ↗

Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial ChemotherapySemantic proximity Read ↗

Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active against Mycobacterium abscessus and Mycobacterium avium, Two Emerging Human PathogensSemantic proximity Read ↗

Dihydrofolate Reductase as a Target for Chemotherapy in ParasitesSemantic proximity Read ↗

High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Semantic proximity Read ↗

Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.Semantic proximity Read ↗

Unveiling the antiviral capabilities of targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2Semantic proximity Read ↗

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessusSemantic proximity Read ↗

In Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered GrowthSemantic proximity Read ↗

Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans.Semantic proximity Read ↗

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetSemantic proximity Read ↗

Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studiesSemantic proximity Read ↗

Driving antimalarial design through understanding of target mechanism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.